ViiV Healthcare Receives FDA Approval of HIV Drug Tivicay - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ViiV Healthcare Receives FDA Approval of HIV Drug Tivicay



ViiV Healthcare, a specialist HIV company of GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received FDA approval for Tivicay (dolutegravir) 50-mg tablets. Tivicay is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12-years and older weighing at least 40 kg (approx. 88 lbs).

ViiV Healthcare was established in November 2009 by GlaxoSmithKline and Pfizer to focus on developing treatments for HIV. The Japanese pharmaceutical company Shionogi joined as a 10% shareholder in October 2012 following a long-term collaboration on the joint development of several integrate inhibitors. ViiV Healthcare has a current portfolio of 11 HIV treatments, which generated 2012 sales of £1.4 billion ($2.2 billion). 

Tivicay is the first new treatment delivered by ViiV Healthcare. ViiV Healthcare also submitted a marketing authorization application for dolutegravir to the EMA in December 2012. Regulatory applications are also being evaluated in other markets worldwide, including Canada, Australia, and Brazil. Submission of regulatory files to support a fixed-dose combination of Tivicay and abacavir/lamivudine is anticipated in 2013.

Source: GlaxoSmithKline

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here